Mazella J, Chabry J, Kitabgi P, et al. Solubilization and characterization of active neurotensin receptors from mouse brain[J]. J Biol Chem, 1988, 263(1): 144.
[2]
Petersen C M, Nielsen M S, Nykjaer A, et al. Molecular identification of a novel candidate sorting receptor purified from human brain by receptor-associated protein affinity chromatography[J]. J Biol Chem, 1997, 272(6): 3599.
[3]
Myers R M, Shearman J W, Kitching M O, et al. Cancer, chemistry, and the cell: molecules that interact with the neurotensin receptors[J]. ACS Chem Biol, 2009, 4(7): 503.
[4]
Labbe-Jullie C, Barroso S, Nicolas-Eteve D, et al. Mutagenesis and modeling of the neurotensin receptor NTR1. Identification of residues that are critical for binding SR 48692, a nonpeptide neurotensin antagonist[J]. J Biol Chem, 1998, 273(26): 16351.
[5]
St-Gelais F, Jomphe C, Trudeau L E. The role of neurotensin in central nervous system pathophysiology: what is the evidence[J]. J Psychiatry Neurosci, 2006, 31(4): 229.
[6]
Mustain W C, Rychahou P G, Evers B M. The role of neurotensin in physiologic and pathologic processes[J]. Curr Opin Endocrinol Diabetes Obes, 2011, 18(1): 75.
[7]
Hall F S, Centeno M, Perona M T, et al. Effects of neurotensin gene knockout in mice on the behavioral effects of cocaine[J]. Psychopharmacology (Berl), 2012, 219(1): 35.
[8]
Rashid M, Wangler N J, Yang L, et al. Functional up-regulation of endopeptidase neurolysin during post-acute and early recovery phases of experimental stroke in mouse brain[J]. J Neurochem, 2014, 129(1): 179.
[9]
Dalvi P S, Nazarians-Armavil A, Purser M J, et al. Glucagon-like peptide-1 receptor agonist, exendin-4, regulates feeding-associated neuropeptides in hypothalamic neuronsin vivo and in vitro[J]. Endocrinology, 2012, 153(5): 2208.
[10]
Gutniak M, Rosenqvist U, Grimelius L, et al. Report on a patient with watery diarrhoea syndrome caused by a pancreatic tumour containing neurotensin, enkephalin and calcitonin[J]. Acta Med Scand, 1980, 208(1/2): 95.
[11]
Yabushita S, Fukamachi K, Tanaka H, et al. Circulating microRNAs in serum of human K-ras oncogene transgenic rats with pancreatic ductal adenocarcinomas[J]. Pancreas, 2012, 41(7): 1013.
[12]
Cheng H, Shi S, Cai X, et al. microRNA signature for human pancreatic cancer invasion and metastasis[J]. Exp Ther Med, 2012, 4(2): 181.
[13]
Ehlers R A, Kim S, Zhang Y, et al. Gut peptide receptor expression in human pancreatic cancers[J]. Ann Surg, 2000, 231(6): 838.
[14]
Wang L, Friess H, Zhu Z, et al. Neurotensin receptor-1 mRNA analysis in normal pancreas and pancreatic disease[J]. Clin Cancer Res, 2000, 6(2): 566.
[15]
Feurle G E, Muller B, Rix E. Neurotensin induces hyperplasia of the pancreas and growth of the gastric antrum in rats[J]. Gut, 1987, 28(Suppl): 19.
[16]
Garcia-Garayoa E, Blauenstein P, Blanc A, et al. A stable neurotensin-based radiopharmaceutical for targeted imaging and therapy of neurotensin receptor-positive tumours[J]. Eur J Nucl Med Mol Imaging, 2009, 36(1): 37.
[17]
Janssen P J, de Visser M, Verwijnen S M, et al. Five stabilized 111In-labeled neurotensin analogs in nude mice bearing HT29 tumors[J]. Cancer Biother Radiopharm, 2007, 22(3): 374.
[18]
Fabbrini M, Falciani C, Lelli B, et al. Tumor imaging with tetrabranched neurotensin[J]. Adv Exp Med Biol, 2009, 611: 437.
[19]
Alshoukr F, Prignon A, Brans L, et al. Novel DOTA-neurotensin analogues for 111In scintigraphy and 68Ga PET imaging of neurotensin receptor-positive tumors[J]. Bioconjug Chem, 2011, 22(7): 1374.
[20]
Lang C, Maschauer S, Hubner H, et al. Synthesis and evaluation of a (18)F-labeled diarylpyrazole glycoconjugate for the imaging of NTS1-positive tumors[J]. J Med Chem, 2013, 56(22): 9361.
[21]
de Lange R, Dimoudis N, Weidle U H. Identification of genes associated with enhanced metastasis of a large cell lung carcinoma cell line[J]. Anticancer Res, 2003, 23(1A): 187.
[22]
Alifano M, Souaze F, Dupouy S, et al. Neurotensin receptor 1 determines the outcome of non-small cell lung cancer[J]. Clin Cancer Res, 2010, 16(17): 4401.
[23]
Goedert M, Reeve J G, Emson P C, et al. Neurotensin in human small cell lung carcinoma[J]. Br J Cancer, 1984, 50(2): 179.
[24]
Ocejo-Garcia M, Ahmed S I, Coulson J M, et al. Use of RT-PCR to detect co-expression of neuropeptides and their receptors in lung cancer[J]. Lung Cancer, 2001, 33(1): 1.
[25]
Moody T W, Carney D N, Korman L Y, et al. Neurotensin is produced by and secreted from classic small cell lung cancer cells[J]. Life Sci, 1985, 36(18): 1727.
[26]
Moody T W, Mahmoud S, Staley J, et al. Neuropeptides elevate cytosolic calcium in small-cell lung cancer cells[J]. Ann N Y Acad Sci, 1988, 551: 280.
[27]
Woll P J, Rozengurt E. Multiple neuropeptides mobilise calcium in small cell lung cancer: effects of vasopressin, bradykinin, cholecystokinin, galanin and neurotensin[J]. Biochem Biophys Res Commun, 1989, 164(1): 66.
[28]
Seufferlein T, Rozengurt E. Galanin, neurotensin, and phorbol esters rapidly stimulate activation of mitogen-activated protein kinase in small cell lung cancer cells[J]. Cancer Res, 1996, 56(24): 5758.
[29]
Moody T W, Chan D, Fahrenkrug J, et al. Neuropeptides as autocrine growth factors in cancer cells[J]. Curr Pharm Des, 2003, 9(6): 495.
[30]
Tallett A, Chilvers E R, MacKinnon A C, et al. Neuropeptides stimulate tyrosine phosphorylation and tyrosine kinase activity in small cell lung cancer cell lines[J]. Peptides, 1996, 17(4): 665.
[31]
Leyton J, Garcia-Marin L, Jensen R T, et al. Neurotensin causes tyrosine phosphorylation of focal adhesion kinase in lung cancer cells[J]. Eur J Pharmacol, 2002, 442(3): 179.
[32]
Sethi T, Rozengurt E. Multiple neuropeptides stimulate clonal growth of small cell lung cancer: effects of bradykinin, vasopressin, cholecystokinin, galanin, and neurotensin[J]. Cancer Res, 1991, 51(13): 3621.
[33]
Davis T P, Crowell S, McInturff B, et al. Neurotensin may function as a regulatory peptide in small cell lung cancer[J]. Peptides, 1991, 12(1): 17.
[34]
Sethi T, Langdon S, Smyth J, et al. Growth of small cell lung cancer cells: stimulation by multiple neuropeptides and inhibition by broad spectrum antagonists in vitro and in vivo[J]. Cancer Res, 1992, 52(9 Suppl): 2737s.
[35]
Moody T W, Chiles J, Casibang M, et al. SR48692 is a neurotensin receptor antagonist which inhibits the growth of small cell lung cancer cells[J]. Peptides, 2001, 22(1): 109.
[36]
Takahashi K, Furukawa C, Takano A, et al. The neuromedin U-growth hormone secretagogue receptor 1b/neurotensin receptor 1 oncogenic signaling pathway as a therapeutic target for lung cancer[J]. Cancer Res, 2006, 66(19): 9408.
[37]
Moody T W, Chan D C, Mantey S A, et al. SR48692 inhibits non-small cell lung cancer proliferation in an EGF receptor-dependent manner[J]. Life Sci, 2014, 100(1): 25.
[38]
Moody T W, Berna M J, Mantey S, et al. Neuromedin B receptors regulate EGF receptor tyrosine phosphorylation in lung cancer cells[J]. Eur J Pharmacol, 2010, 637(1/3): 38.
[39]
Moody T W, Osefo N, Nuche-Berenguer B, et al. Pituitary adenylate cyclase-activating polypeptide causes tyrosine phosphorylation of the epidermal growth factor receptor in lung cancer cells[J]. J Pharmacol Exp Ther, 2012, 341(3): 873.
[40]
Wakabayashi-Nakao K, Maruyama K, Ishii H, et al. Investigation of proNT/NMN secretion from small cell lung carcinoma cells using a mouse xenograft model[J]. Oncol Rep, 2012, 28(4): 1181.
[41]
Jacobo-Herrera N J, Perez-Plasencia C, Camacho-Zavala E, et al. Clinical evidence of the relationship between aspirin and breast cancer risk (review)[J]. Oncol Rep, 2014, 32(2): 451.
[42]
Elek J, Pinzon W, Park K H, et al. Relevant genomics of neurotensin receptor in cancer[J]. Anticancer Res, 2000, 20(1A): 53.
[43]
Somai S, Gompel A, Rostene W, et al. Neurotensin counteracts apoptosis in breast cancer cells[J]. Biochem Biophys Res Commun, 2002, 295(2): 482.
[44]
Souaze F, Dupouy S, Viardot-Foucault V, et al. Expression of neurotensin and NT1 receptor in human breast cancer: a potential role in tumor progression[J]. Cancer Res, 2006, 66(12): 6243.
[45]
Heakal Y, Kester M. Nanoliposomal short-chain ceramide inhibits agonist-dependent translocation of neurotensin receptor 1 to structured membrane microdomains in breast cancer cells[J]. Mol Cancer Res, 2009, 7(5): 724.
[46]
Watters J J, Dorsa D M. Transcriptional effects of estrogen on neuronal neurotensin gene expression involve cAMP/protein kinase A-dependent signaling mechanisms[J]. J Neurosci, 1998, 18(17): 6672.
[47]
Dupouy S, Viardot-Foucault V, Alifano M, et al. The neurotensin receptor-1 pathway contributes to human ductal breast cancer progression[J]. PLoS ONE, 2009, 4(1): e4223.
[48]
Castillo-Rodriguez R A, Arango-Rodriguez M L, Escobedo L, et al. Suicide HSVtk gene delivery by neurotensin-polyplex nanoparticles via the bloodstream and GCV Treatment specifically inhibit the growth of human MDA-MB-231 triple negative breast cancer tumors xenografted in athymic mice[J]. PLoS ONE, 2014, 9(5): e97151.
[49]
Brodeur G M. Neuroblastoma: biological insights into a clinical enigma[J]. Nat Rev Cancer, 2003, 3(3): 203.
[50]
Schwab M, Westermann F, Hero B, et al. Neuroblastoma: biology and molecular and chromosomal pathology[J]. Lancet Oncol, 2003, 4(8): 472.
[51]
Gustafson W C, De Berry B B, Evers B M, et al. Role of gastrointestinal hormones in neuroblastoma[J]. World J Surg, 2005, 29(3): 281.
[52]
Tavares D, Tully K, Dobner P R. Sequences required for induction of neurotensin receptor gene expression during neuronal differentiation of N1E-115 neuroblastoma cells[J]. J Biol Chem, 1999, 274(42): 30066.
[53]
Najimi M, Hermans E, Rostene W, et al. Transcriptional regulation of the tyrosine hydroxylase gene by neurotensin in human neuroblastoma CHP212 cells[J]. Metab Brain Dis, 2001, 16(3/4): 165.
[54]
Schulte J H, Kirfel J, Lim S, et al. Transcription factor AP2alpha (TFAP2a) regulates differentiation and proliferation of neuroblastoma cells[J]. Cancer Lett, 2008, 271(1): 56.
[55]
Rubio-Zapata H A, Rembao-Bojorquez J D, Arango-Rodriguez M L, et al. NT-polyplex: a new tool for therapeutic gene delivery to neuroblastoma tumors[J]. Cancer Gene Ther, 2009, 16(7): 573.
[56]
Lang H, Oldhafer K J, Weimann A, et al. Liver transplantation for metastatic neuroendocrine tumors[J]. Ann Surg, 1997, 225(4): 347.
[57]
Evers B M, Ishizuka J, Townsend C M Jr., et al. Expression of neurotensin messenger RNA in a human carcinoid tumor[J]. Ann Surg, 1991, 214(4): 448.
[58]
Di Florio A, Sancho V, Moreno P, et al. Gastrointestinal hormones stimulate growth of foregut neuroendocrine tumors by transactivating the EGF receptor[J]. Biochim Biophys Acta, 2013, 1833(3): 573.
[59]
Valentino J D, Li J, Zaytseva Y Y, et al. Cotargeting the PI3K and RAS pathways for the treatment of neuroendocrine tumors[J]. Clin Cancer Res, 2014, 20(5): 1212.
[60]
Kim J T, Liu C, Zaytseva Y Y, et al. Neurotensin, a novel target of Wnt/beta-catenin pathway, promotes growth of neuroendocrine tumor cells[J]. Int J Cancer, 2015,136(6): 1475.
[61]
Nakaizumi A, Uehara H, Baba M, et al. Enhancement by neurotensin of hepatocarcinogenesis by N-nitrosomorpholine in Sprague-Dawley rats[J]. Cancer Lett, 1996, 110(1/2): 57.
[62]
Tang K H, Ma S, Lee T K, et al. CD133(+) liver tumor-initiating cells promote tumor angiogenesis, growth, and self-renewal through neurotensin/interleukin-8/CXCL1 signaling[J]. Hepatology, 2012, 55(3): 807.
[63]
Yu J, Ren X, Chen Y, et al. Dysfunctional activation of neurotensin/IL-8 pathway in hepatocellular carcinoma is associated with increased inflammatory response in microenvironment, more epithelial mesenchymal transition in cancer and worse prognosis in patients[J]. PLoS ONE, 2013, 8(2): e56069.
[64]
Malouf G G, Job S, Paradis V, et al. Transcriptional profiling of pure fibrolamellar hepatocellular carcinoma reveals an endocrine signature[J]. Hepatology, 2014, 59(6): 2228.
[65]
Reubi J C, Waser B, Schaer J C, et al. Neurotensin receptors in human neoplasms: high incidence in Ewing\'s sarcomas[J]. Int J Cancer, 1999, 82(2): 213.
[66]
Rodriguez Y, Almeida T A, Valladares F, et al. Neurotensin and neurotensin receptor 1 expression in human myometrium and uterine leiomyomas[J]. Biol Reprod, 2010, 83(4): 641.
[67]
Rodriguez Y, Baez D, de Oca F M, et al. Comparative analysis of the ERalpha/ERbeta ratio and neurotensin and its high-affinity receptor in myometrium, uterine leiomyoma, atypical leiomyoma, and leiomyosarcoma[J]. Int J Gynecol Pathol, 2011, 30(4): 354.
[68]
Saada S, Marget P, Fauchais A L, et al. Differential expression of neurotensin and specific receptors, NTSR1 and NTSR2, in normal and malignant human B lymphocytes[J]. J Immunol, 2012, 189(11): 5293.
[69]
Ramez M, Bagot M, Nikolova M, et al. Functional characterization of neurotensin receptors in human cutaneous T cell lymphoma malignant lymphocytes[J]. J Invest Dermatol, 2001, 117(3): 687.
[70]
Shimizu S, Tsukada J, Sugimoto T, et al. Identification of a novel therapeutic target for head and neck squamous cell carcinomas: a role for the neurotensin-neurotensin receptor 1 oncogenic signaling pathway[J]. Int J Cancer, 2008, 123(8): 1816.
[71]
Haase C, Bergmann R, Oswald J, et al. Neurotensin receptors in adeno- and squamous cell carcinoma[J]. Anticancer Res, 2006, 26(5A): 3527.
Servotte S, Camby I, Debeir O, et al. The in vitro influences of neurotensin on the motility characteristics of human U373 glioblastoma cells[J]. Neuropathol Appl Neurobiol, 2006, 32(6): 575.
[74]
Tatsuta M, Iishi H, Baba M, et al. Promotion by neurotensin of gastric carcinogenesis induced by N-methyl-N\'-nitro-N-nitrosoguanidine in Wistar rats[J]. Cancer Res, 1989, 49(4): 843.
[75]
Gromova P, Rubin B P, Thys A, et al. Neurotensin receptor 1 is expressed in gastrointestinal stromal tumors but not in interstitial cells of Cajal[J]. PLoS ONE, 2011, 6(2): e14710.
[76]
Zhang Y, Zhu S, Yi L, et al. Neurotensin receptor1 antagonist SR48692 reduces proliferation by inducing apoptosis and cell cycle arrest in melanoma cells[J]. Mol Cell Biochem, 2014, 389(1/2): 1.
[77]
Giorgi R R, Chile T, Bello A R, et al. Expression of neurotensin and its receptors in pituitary adenomas[J]. J Neuroendocrinol, 2008, 20(9): 1052.
[78]
Alifano M, Loi M, Camilleri-Broet S, et al. Neurotensin expression and outcome of malignant pleural mesothelioma[J]. Biochimie, 2010, 92(2): 164.
[79]
Carraway R E, Gui X, Cochrane D E. Ca2+ channel blockers enhance neurotensin (NT) binding and inhibit NT-induced inositol phosphate formation in prostate cancer PC3 cells[J]. J Pharmacol Exp Ther, 2003, 307(2): 640.
[80]
Wang X, Wang Q, Ives K L, et al. Curcumin inhibits neurotensin-mediated interleukin-8 production and migration of HCT116 human colon cancer cells[J]. Clin Cancer Res, 2006, 12(18): 5346.
[81]
Hassan S, Carraway R E. Involvement of arachidonic acid metabolism and EGF receptor in neurotensin-induced prostate cancer PC3 cell growth[J]. Regul Pept, 2006, 133(1/3): 105.
[82]
Souaze F, Viardot-Foucault V, Roullet N, et al. Neurotensin receptor 1 gene activation by the Tcf/beta-catenin pathway is an early event in human colonic adenomas[J]. Carcinogenesis, 2006, 27(4): 708.
[83]
Wang X, Jackson L N, Johnson S M, et al. Suppression of neurotensin receptor type 1 expression and function by histone deacetylase inhibitors in human colorectal cancers[J]. Mol Cancer Ther, 2010, 9(8): 2389.
Dolais-Kitabgi J, Kitabgi P, Brazeau P, et al. Effect of neurotensin on insulin, glucagon, and somatostatin release from isolated pancreatic islets[J]. Endocrinology, 1979, 105(1): 256.
[109]
Coppola T, Beraud-Dufour S, Antoine A, et al. Neurotensin protects pancreatic beta cells from apoptosis[J]. Int J Biochem Cell Biol, 2008, 40(10): 2296.
[110]
Beraud-Dufour S, Abderrahmani A, Noel J, et al. Neurotensin is a regulator of insulin secretion in pancreatic beta-cells[J]. Int J Biochem Cell Biol, 2010, 42(10): 1681.
[111]
Markowska A, Nussdorfer G G, Malendowicz L K. Proliferogenic effect of neurotensin (NT) and neuromedin-N (NMN) on the rat adrenal cortex: evidence that angiotensin-II mediates the effect of NMN, but not of NT[J]. Neuropeptides, 1994, 27(2): 91.
[112]
Mazella J, Zsurger N, Navarro V, et al. The 100-kDa neurotensin receptor is gp95/sortilin, a non-G-protein-coupled receptor[J]. J Biol Chem, 1998, 273(41): 26273.
[113]
Tanaka K, Masu M, Nakanishi S. Structure and functional expression of the cloned rat neurotensin receptor[J]. Neuron, 1990, 4(6): 847.
[114]
Ishizuka J, Townsend C M Jr., Thompson J C. Neurotensin regulates growth of human pancreatic cancer[J]. Ann Surg, 1993, 217(5): 439.
[115]
Iwase K, Evers B M, Hellmich M R, et al. Inhibition of neurotensin-induced pancreatic carcinoma growth by a nonpeptide neurotensin receptor antagonist, SR48692[J]. Cancer, 1997, 79(9): 1787.
[116]
Mijatovic T, Gailly P, Mathieu V, et al. Neurotensin is a versatile modulator of in vitro human pancreatic ductal adenocarcinoma cell (PDAC) migration[J]. Cell Oncol, 2007, 29(4): 315.
[117]
Olszewski U, Hamilton G. Neurotensin signaling induces intracellular alkalinization and interleukin-8 expression in human pancreatic cancer cells[J]. Mol Oncol, 2009, 3(3): 204.
[118]
Olszewski U, Hlozek M, Hamilton G. Activation of Na+/H+ exchanger 1 by neurotensin signaling in pancreatic cancer cell lines[J]. Biochem Biophys Res Commun, 2010, 393(3): 414.
[119]
Jemal A, Bray F, Center M M, et al. Global cancer statistics[J]. CA Cancer J Clin, 2011, 61(2): 69.
[120]
Taylor R M, Severns V, Brown D C, et al. Prostate cancer targeting motifs: expression of alphanu beta3, neurotensin receptor 1, prostate specific membrane antigen, and prostate stem cell antigen in human prostate cancer cell lines and xenografts[J]. Prostate, 2012, 72(5): 523.
[121]
Sehgal I, Powers S, Huntley B, et al. Neurotensin is an autocrine trophic factor stimulated by androgen withdrawal in human prostate cancer[J]. Proc Natl Acad Sci USA, 1994, 91(11): 4673.
[122]
Lee L F, Guan J, Qiu Y, et al. Neuropeptide-induced androgen independence in prostate cancer cells: roles of nonreceptor tyrosine kinases Etk/Bmx, Src, and focal adhesion kinase[J]. Mol Cell Biol, 2001, 21(24): 8385.
[123]
Seethalakshmi L, Mitra S P, Dobner P R, et al. Neurotensin receptor expression in prostate cancer cell line and growth effect of NT at physiological concentrations[J]. Prostate, 1997, 31(3): 183.
[124]
Valerie N C, Casarez E V, Dasilva J O, et al. Inhibition of neurotensin receptor 1 selectively sensitizes prostate cancer to ionizing radiation[J]. Cancer Res, 2011, 71(21): 6817.
[125]
Vias M, Burtt G, Culig Z, et al. A role for neurotensin in bicalutamide resistant prostate cancer cells[J]. Prostate, 2007, 67(2): 190.
[126]
Swift S L, Burns J E, Maitland N J. Altered expression of neurotensin receptors is associated with the differentiation state of prostate cancer[J]. Cancer Res, 2010, 70(1): 347.
[127]
Almeida T A, Rodriguez Y, Hernandez M, et al. Differential expression of new splice variants of the neurotensin receptor 1 gene in human prostate cancer cell lines[J]. Peptides, 2010, 31(2): 242.
[128]
Evers B M, Ishizuka J, Chung D H, et al. Neurotensin expression and release in human colon cancers[J]. Ann Surg, 1992, 216(4): 423.
[129]
Rovere C, Barbero P, Maoret J J, et al. Pro-neurotensin/neuromedin N expression and processing in human colon cancer cell lines[J]. Biochem Biophys Res Commun, 1998, 246(1): 155.
[130]
Maoret J J, Pospai D, Rouyer-Fessard C, et al. Neurotensin receptor and its mRNA are expressed in many human colon cancer cell lines but not in normal colonic epithelium: binding studies and RT-PCR experiments[J]. Biochem Biophys Res Commun, 1994, 203(1): 465.
[131]
Tasuta M, Iishi H, Baba M, et al. Enhancement by neurotensin of experimental carcinogenesis induced in rat colon by azoxymethane[J]. Br J Cancer, 1990, 62(3): 368.
[132]
Maoret J J, Anini Y, Rouyer-Fessard C, et al. Neurotensin and a non-peptide neurotensin receptor antagonist control human colon cancer cell growth in cell culture and in cells xenografted into nude mice[J]. Int J Cancer, 1999, 80(3): 448.
[133]
Gui X, Guzman G, Dobner P R, et al. Increased neurotensin receptor-1 expression during progression of colonic adenocarcinoma[J]. Peptides, 2008, 29(9): 1609.
[134]
Gui X, Liu S, Yan Y, et al. Neurotensin receptor 1 overexpression in inflammatory bowel diseases and colitis-associated neoplasia[J]. World J Gastroenterol, 2013, 19(28): 4504.
[135]
Bossard C, Souaze F, Jarry A, et al. Over-expression of neurotensin high-affinity receptor 1 (NTS1) in relation with its ligand neurotensin (NT) and nuclear beta-catenin in inflammatory bowel disease-related oncogenesis[J]. Peptides, 2007, 28(10): 2030.
[136]
Bugni J M, Rabadi L A, Jubbal K, et al. The neurotensin receptor-1 promotes tumor development in a sporadic but not an inflammation-associated mouse model of colon cancer[J]. Int J Cancer, 2012, 130(8): 1798.
[137]
Chowdhury M A, Peters A A, Roberts-Thomson S J, et al. Effects of differentiation on purinergic and neurotensin-mediated calcium signaling in human HT-29 colon cancer cells[J]. Biochem Biophys Res Commun, 2013, 439(1): 35.
[138]
Sgourakis G, Papapanagiotou A, Kontovounisios C, et al. The combined use of serum neurotensin and IL-8 as screening markers for colorectal cancer[J]. Tumour Biol, 2014, 35(6): 5993.
[139]
Hillairet De Boisferon M, Raguin O, Thiercelin C, et al. Improved tumor selectivity of radiolabeled peptides by receptor and antigen dual targeting in the neurotensin receptor model[J]. Bioconjug Chem, 2002, 13(3): 654.
[140]
Garcia-Garayoa E, Blauenstein P, Bruehlmeier M, et al. Preclinical evaluation of a new, stabilized neurotensin(8-13) pseudopeptide radiolabeled with (99m)tc[J]. J Nucl Med, 2002, 43(3): 374.
[141]
Bruehlmeier M, Garayoa E G, Blanc A, et al. Stabilization of neurotensin analogues: effect on peptide catabolism, biodistribution and tumor binding[J]. Nucl Med Biol, 2002, 29(3): 321.
[142]
Nock B A, Nikolopoulou A, Reubi J C, et al. Toward stable N4-modified neurotensins for NTS1-receptor-targeted tumor imaging with 99mTc[J]. J Med Chem, 2006, 49(15): 4767.
[143]
Garcia-Garayoa E, Maes V, Blauenstein P, et al. Double-stabilized neurotensin analogues as potential radiopharmaceuticals for NTR-positive tumors[J]. Nucl Med Biol, 2006, 33(4): 495.
[144]
Ryder N M, Guha S, Hines O J, et al. G protein-coupled receptor signaling in human ductal pancreatic cancer cells: neurotensin responsiveness and mitogenic stimulation[J]. J Cell Physiol, 2001, 186(1): 53.
[145]
Guha S, Rey O, Rozengurt E. Neurotensin induces protein kinase C-dependent protein kinase D activation and DNA synthesis in human pancreatic carcinoma cell line PANC-1[J]. Cancer Res, 2002, 62(6): 1632.
[146]
Kisfalvi K, Hurd C, Guha S, et al. Induced overexpression of protein kinase D1 stimulates mitogenic signaling in human pancreatic carcinoma PANC-1 cells[J]. J Cell Physiol, 2010, 223(2): 309.
[147]
Ehlers R A, Zhang Y, Hellmich M R, et al. Neurotensin-mediated activation of MAPK pathways and AP-1 binding in the human pancreatic cancer cell line, MIA PaCa-2[J]. Biochem Biophys Res Commun, 2000, 269(3): 704.
[148]
Wang Q, Zhou Y, Evers B M. Neurotensin phosphorylates GSK-3alpha/beta through the activation of PKC in human colon cancer cells[J]. Neoplasia, 2006, 8(9): 781.
[149]
Bakirtzi K, Hatziapostolou M, Karagiannides I, et al. Neurotensin signaling activates microRNAs-21 and -155 and Akt, promotes tumor growth in mice, and is increased in human colon tumors[J]. Gastroenterology, 2011, 141(5): 1749.
[150]
Zhao D, Zhan Y, Zeng H, et al. Neurotensin stimulates expression of early growth response gene-1 and EGF receptor through MAP kinase activation in human colonic epithelial cells[J]. Int J Cancer, 2007, 120(8): 1652.
[151]
Amorino G P, Deeble P D, Parsons S J. Neurotensin stimulates mitogenesis of prostate cancer cells through a novel c-Src/Stat5b pathway[J]. Oncogene, 2007, 26(5): 745.
[152]
Kataoka H. EGFR ligands and their signaling scissors, ADAMs, as new molecular targets for anticancer treatments[J]. J Dermatol Sci, 2009, 56(3): 148.
[153]
Sanderson M P, Dempsey P J, Dunbar A J. Control of ErbB signaling through metalloprotease mediated ectodomain shedding of EGF-like factors[J]. Growth Factors, 2006, 24(2): 121.
[154]
Hassan S, Dobner P R, Carraway R E. Involvement of MAP-kinase, PI3-kinase and EGF-receptor in the stimulatory effect of Neurotensin on DNA synthesis in PC3 cells[J]. Regul Pept, 2004, 120(1/3): 155.
[155]
Zhao D, Keates A C, Kuhnt-Moore S, et al. Signal transduction pathways mediating neurotensin-stimulated interleukin-8 expression in human colonocytes[J]. J Biol Chem, 2001, 276(48): 44464.
[156]
Mitra S P, Carraway R E. Synergistic effects of neurotensin and beta-adrenergic agonist on 3,5-cyclic adenosine monophosphate accumulation and DNA synthesis in prostate cancer PC3 cells[J]. Biochem Pharmacol, 1999, 57(12): 1391.
[157]
Carraway R E, Hassan S, Cochrane D E. Regulation of neurotensin receptor function by the arachidonic acid-lipoxygenase pathway in prostate cancer PC3 cells[J]. Prostaglandins Leukot Essent Fatty Acids, 2006, 74(2): 93.
Carraway R, Leeman S E. The isolation of a new hypotensive peptide, neurotensin, from bovine hypothalami[J]. J Biol Chem, 1973, 248(19): 6854.
[163]
Dupouy S, Mourra N, Doan V K, et al. The potential use of the neurotensin high affinity receptor 1 as a biomarker for cancer progression and as a component of personalized medicine in selective cancers[J]. Biochimie, 2011, 93(9): 1369.
[164]
Thomas R P, Hellmich M R, Townsend C M, et al. Role of gastrointestinal hormones in the proliferation of normal and neoplastic tissues[J]. Endocr Rev, 2003, 24(5): 571.
[165]
Wu Z, Martinez-Fong D, Tredaniel J, et al. Neurotensin and its high affinity receptor 1 as a potential pharmacological target in cancer therapy[J]. Front Endocrinol (Lausanne), 2012, 3: 184.
[166]
Carraway R, Leeman S E. The amino acid sequence of a hypothalamic peptide, neurotensin[J]. J Biol Chem, 1975, 250(5): 1907.
[167]
Lambert P D, Gross R, Nemeroff C B, et al. Anatomy and mechanisms of neurotensin-dopamine interactions in the central nervous system[J]. Ann N Y Acad Sci, 1995, 757: 377.
[168]
Dobner P R, Barber D L, Villa-Komaroff L, et al. Cloning and sequence analysis of cDNA for the canine neurotensin/neuromedin N precursor[J]. Proc Natl Acad Sci USA, 1987, 84(10): 3516.
[169]
Kislauskis E, Bullock B, McNeil S, et al. The rat gene encoding neurotensin and neuromedin N. Structure, tissue-specific expression, and evolution of exon sequences[J]. J Biol Chem, 1988, 263(10): 4963.
[170]
Kitabgi P. Differential processing of pro-neurotensin/neuromedin N and relationship to pro-hormone convertases[J]. Peptides, 2006, 27(10): 2508.
[171]
Kitabgi P, De Nadai F, Rovere C, et al. Biosynthesis, maturation, release, and degradation of neurotensin and neuromedin N[J]. Ann N Y Acad Sci, 1992, 668: 30.
[172]
Uhl G R, Snyder S H. Regional and subcellular distributions of brain neurotensin[J]. Life Sci, 1976, 19(12): 1827.
[173]
Binder E B, Kinkead B, Owens M J, et al. Neurotensin and dopamine interactions[J]. Pharmacol Rev, 2001, 53(4): 453.
[174]
Dubuc I, Sarret P, Labbe-Jullie C, et al. Identification of the receptor subtype involved in the analgesic effect of neurotensin[J]. J Neurosci, 1999, 19(1): 503.
[175]
Popp E, Schneider A, Vogel P, et al. Time course of the hypothermic response to continuously administered neurotensin[J]. Neuropeptides, 2007, 41(5): 349.
[176]
Pert C B, Ruff M R, Weber R J, et al. Neuropeptides and their receptors: a psychosomatic network[J]. J Immunol, 1985, 135(2 Suppl): 820s.
[177]
Weiss D W, Hirt R, Tarcic N, et al. Studies in psychoneuroimmunology: psychological, immunological, and neuroendocrinological parameters in Israeli civilians during and after a period of Scud missile attacks[J]. Behav Med, 1996, 22(1): 5.
[178]
Evers B M. Neurotensin and growth of normal and neoplastic tissues[J]. Peptides, 2006, 27(10): 2424.
[179]
Zhao D, Pothoulakis C. Effects of NT on gastrointestinal motility and secretion, and role in intestinal inflammation[J]. Peptides, 2006, 27(10): 2434.
[180]
Andersson S, Chang D, Folkers K, et al. Inhibition of gastric acid secretion in dogs by neurotensin[J]. Life Sci, 1976, 19(3): 367.
[181]
Andersson S, Rosell S, Hjelmquist U, et al. Inhibition of gastric and intestinal motor activity in dogs by (Gln4) neurotensin[J]. Acta Physiol Scand, 1977, 100(2): 231.
[182]
Armstrong M J, Parker M C, Ferris C F, et al. Neurotensin stimulates [3H]oleic acid translocation across rat small intestine[J]. Am J Physiol, 1986, 251(6 Pt 1): G823.
[183]
Baca I, Feurle G E, Haas M, et al. Interaction of neurotensin, cholecystokinin, and secretin in the stimulation of the exocrine pancreas in the dog[J]. Gastroenterology, 1983, 84(3): 556.
